放射免疫治疗中单克隆抗体药物研究现状

doi:10.7538/tws.2013.26.02.0122

摘要/Abstract

摘要：

近20年来，放射免疫治疗( radioimmunotherapy，RIT)在肿瘤治疗方面取得了显著进展，已成功应用于血液循环系统恶性肿瘤治疗，但对于肝癌、肺癌等实体肿瘤的治疗尚有待突破。本文就目前RIT常用的放射性核素、单克隆抗体和药物的研究及应用现状进行了综述。

关键词: font-family: 宋体">放射性核素font-family: 'Times New Roman'">, font-family: 宋体">单克隆抗体font-family: 'Times New Roman'">, font-family: 宋体">靶向性font-family: 'Times New Roman'">, font-family: 宋体">放射免疫治疗

Abstract:

Radioimmuntherapy (RIT) wasone of the most important progresses in the field of cancer therapy over thepast 20 years. It has been successfully appied in the treatment of blood systemtumors such as NHL. For the utilization of RIT in therapy of solid tumors,however, development of more effective monoclonal antibodies, labeling methodsand so on are needed. The current status of radionuclides, monoclonalantibodies and drugs commonly used in the RIT were briefly reviewed.

Key words: font-family: 'Times New Roman'">radionuclide, monoclonalantibody, targeting, radioimmunotherapy

潘俊男;程作用. 放射免疫治疗中单克隆抗体药物研究现状[J]. 同位素, 2013, 26(2): 122-128.

PAN Jun-nan;CHENGZuo-yong. Current Research Status ofRadioimmunotherapy Monoclonal Antibody Drug[J]. Journal of Isotopes, 2013, 26(2): 122-128.

参考文献

[1]Magerstadt M. Antibody Conjugates and MalignantDisease[M].CRC Press： Boca Raton, 1991: 42-45.

[2]Press OW.Radioimmunotherapy for non-Hodgkin's lymphomas:A historical perspective[J].Seminars in Oncology, 2003, 30(2): 10-21.

[3]张迎,袁胜利. 曲妥珠单抗在乳癌放射免疫治疗的研究进展[J]. 齐鲁医学杂志, 2011 , 26(4):372-376.ZhangYing, Yuan Shengli. Research progress of trastuzumab in breast cancerradioimmunotherapy[J]. Medical Journal of Qilu, 2011, 26(4):372-376（in Chinese）.

[4]Andrew BC, Brechbiel MW. Development of rad-ioimmunotherapeuticand diagnostic antibodies:an inside-out view[J]. Nuclear Medicine and Biology,2007, 34: 757-778.

[5]CD20：单抗药物的“宠儿”[EB/OL][2011-06-17].http://www.51atgc.com/BioSpecial/Mantibody/2011-06-17/9810_2.html.

[6]Hagenbeek A, Plesner T, Johnson P, et al. Hu Max CD20，anovelfully human anti-CD20 monoclonal antibody: Results of a phase I/II trialin relapsed or refractory follicular non-Hodgkin's lymphoma[J]. Blood, 2005,106(4): 4760.

[7]康银花, 范鸣. 抗CD22单克隆抗体Epratuzumab[J]. 药学进展, 2009, 33(3): 138-139.

Kang Yinhua , Fan Ming. Anti-CD22 monoclonal antibodyEpratuzumab[J]. Progress in Pharmaceutical Sciences, 2009, 33(3): 138-139（inChinese）.

[8]Legrand O, Perrot JY, BaudardM, et al. TheImmunophenotype of 177 Adluts with AcuteMyeloid Leukemia: Proposal of aPrognostic Score[J]. Blood, 2000, 96(3): 870-877.

[9]FDA: Pfizer Voluntarily Withdraws Cancer TreatmentMylotarg from US Market[EB/OL] (2010-06-22).http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm.

[10]Mylotarg[EB/OL]. [2008-06-24].http://www.rxlist.com/mylotarg-drug.htm.

[11]Valabrega G, Aglietta M. Trastuzumab: mechanism ofaction, resistance and future perspectives in HER2-over expressin g breastcancer[J]. Annals of Oncology, 2007, 18(6): 977-984.

[12]Viloria PA, Crombet T. Acquired resistance to theantitum or effect of epidermal growth factor receptor-blocking antibodies invivo: a role f or altered tumor angiogenesis[J]. Cancer Research, 2001, 61: 5091-5101.

[13]Chang JC,Mayer IA,Forero-Torres A, et al. TBCRC006:a multicenter phase Ⅱ study of neoadjuvant lapatinibandtrastuzumab in patients with HER2-overexpressing breastcancer：2011 ASCO Annual Meeting, McCormick Place in Chicago: 2011[C]. Chincago：AmericanSociety of Clinical Oncology, 2011: 505.

[14]张冰.T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼[EB/OL] (2012-06-06).http://www.chinapharm.com.cn/html/kyxx/1338948602156.html.

[15]陈静.中国首个晚期胃癌靶向药物上市[EB/OL] (2012-10-15).http://www.chinapharm.com.cn/html/kyxx/1350267351874.html.

[16]Kainski MS, Zelenetz AD, Press OW, et al. Pivotalstudy of iodine I131 tositumomab for chemotherapy refractory low-gradeor transformed low-grade B-cell non-Hodgk in’slymphomas [J]. American Society of Clinical Oncology, 2001, 19(19): 3918-3928.

[17]Mark C.Via. Monoclonal Antibodies:Pipeline Analysisand Competitive Assessment[M]. Cambridge Healthtech Institute, 2009: 96-98.

[18]Sharkey RM, Brenner A, Burton J, et al.Radioimmunotherapy of non-Hodgkin′s lymphoma with ⁹⁰Y-DOTAhumanized anti-CD22 IgG (⁹⁰Y-Epratuzumab): do tumor targeting anddosimetry predict therapeutic response? [J].Journal of Nuclear Medicine, 2003, 44:2000-2018

[19]Linden O, Hindorf C, Cavallin-Stahl E, et al. Do-se-fractionatedradioimmunotherapy in non-Hodgkin′s lymphoma using DOTA-conjugated,⁹⁰Y-radiolabeled, humanized anti-CD22 monoclonal antibody,epratuzumab[J]. Clin Cancer Research, 2005, 11: 5215-5222.

[20]Jurcic JG, Larson SM, SgourosG, et al.Targetedalpha particle immunotherapy for myeloid leukemia[J]. Blood, 2002, 100: 1233-1239.

[21]杨志学,蒋国勤. ¹³¹I-Hercentin在乳腺癌裸鼠模型中的体内分布[J]. 苏州大学学报(医学版),2011, 31(6): 909-911.Yang Zhixue, Jiang Guoqin. Biodistribution of ¹³¹I-Hercentinin Breast Cancer Xenograft[J]. Suzhou University Journal of Medical, 2011,31(6): 909-911（in Chinese）.

[22]Zhang Xiao. Novel therapeutic approaches for ma-mmarycancer[J]. Dissertation Abstracts International, 2007, 68(6): 3706.

[23]Griffths GL, Goldenberg DM, Knapp FF, et al.Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188for radioimmunotherapy: labeling and animal biodistribution studies[J]. CancerResearch, 1991,51(17): 4594-4602.

[24]Allen BJ, Rizvi SLY. In vitro and preclinicaltarteged alpha therapy for melanoma, breast , prostate and colorectalcancers[J]. Crit Rev Oncol Hematol, 2001, 39(1-2): 139-146.

[25]Danny L, Costantini CC. ¹¹¹In-LabeledTrastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): AnAuger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified BreastCancer[J]. Journal of Nuclear Medicine, 2007, 48:1357-1368.

[26]王禹冰. 关于全球首个肺癌放射免疫治疗新药——唯美生Vivatuxin[EB/OL] (2011-10-08). http://www.haodf.com/zhuanjiaguandian/wyb95117_528615866.htm.

[27]郭晓东, 孙婷, 李珊珊. 碘[¹³¹I]美妥昔单抗注射液联合TACE治疗原发性肝癌的效果分析[J]. 中国现代医学杂志, 2011, 21(10): 1206-1208.

Guo Xiaodong, Sun Ting, Li Shanshan. The effect ofiodine[¹³¹I] metuximab injection combined with TACE on primary livercancer[J]. China Journal of Modern Medicine, 2011, 21(10): 1206-1208（inChinese）.

[28]Zalutsky MR, Reardon DA, Akabani G et al. ClinicalExperience with Particle Emitting ²¹¹At: Treatment of RecurrentBrain Tumor Patients with ²¹¹At-Labeled Chimeric AntitenascinMonoclonal Antibody 81C6[J]. Journal of Nuclear Medicine, 2007, 49(1): 30-38.

[29]Paganelli G, Chinol M. Radioimmunotherapy: isavidin-biotinpret argeting the preferred choice among pretargeting methods?[J].Journal of Nuclear Medicine, 2003, 30: 773.

[30]汪静, 邓敬兰. RIT在肿瘤临床治疗中的应用[J]. 同位素, 2000, 13(4): 239-242.Wang Jing,Deng Jinglian. Application of RIT in Clinical Therapy of Tumors[J]. Journal ofIsotopes, 13(4): 239-242（in Chinese）.

[31]Gregory Lee, Rui-Ai Chu, Hong Hoi Ting. Preclinical assessment of anti-cancerdrugs by using RP215 monoclonal antibody[J]. Cancer Biology & Therapy,2009, 8(2): 161-166.